VIR4:05 PMVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026Presentation / Abstract • Phase 2vir.bio
VIR4:05 PMVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Resultsvir.bio
VIR4:05 PMVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conferencevir.bio
VIR8:05 AMVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancervir.bio
VIR8:05 AMVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerTrial Start • Phase 1vir.bio